A webinar hosted by GEN will explore how enzymatic DNA synthesis and optimized gene design can enhance antibody expression. The event, scheduled for Thursday, June 11, 2026, at 8:00 PDT (11:00 EDT, 15:00 GMT), features Justin Byers from Ansa Biotechnologies and Daniel Lin-Arlow, PhD.
Byers will present a controlled benchmarking study comparing different codon optimization strategies for antibody expression. He highlights that AI-optimized sequences outperformed traditional methods in terms of transient expression titers under matched conditions (CHO and HEK293). Additionally, these optimized sequences included complex features such as GC skew and repeats, which were effectively manufactured by Ansa’s enzymatic DNA synthesis platform.
Lin-Arlow will discuss the benefits of Ansa's enzymatic DNA synthesis technology for antibody production, cell and gene therapies, and synthetic biology applications. Key points include an AI-powered codon optimization strategy that improves transient expression yield, the importance of controlled benchmarking under standardized conditions, integrating rigorous sequence evaluation upstream to reduce development risks, and addressing complex sequences with high or low GC content, secondary structures, inverted terminal repeats (ITRs), and hom
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
